Please Amend the Claims as follows:

Claim:

4. (Currently amended) A pharmaceutical formulation comprising an aqueous carrier liquid having dissolved therein (a) an ester of fluticasone or a solvate thereof as medicament, wherein the ester of fluticasone is a compound of formula (I)



(I)

wherein R represents furan-2-yl. and (b) a solubilising agent for assisting the solubilisation of the medicament in the aqueous carrier liquid.

6. (cancelled) ~~A pharmaceutical formulation comprising an aqueous carrier liquid having dissolved therein (a) an ester of fluticasone or a solvate thereof as medicament and (b) a solubilising agent for assisting the solubilisation of the medicament in the aqueous carrier liquid, wherein the solubilising agent is a surfactant selected from the group consisting of a α-[4-(1,1,3,3-tetramethylbutyl)phenyl]-ω-hydroxypoly(oxy-1,2-ethanediyl) polymer (also known as a octylphenoxypolyethoxyethanol) and a 4-(1,1,3,3-Tetramethylbutyl)phenol polymer with formaldehyde and oxirane.~~

7. (Original) A pharmaceutical formulation according to claim 4 wherein the solubilising agent is a surfactant selected from the group consisting of a α-[4-(1,1,3,3-tetramethylbutyl)phenyl]-ω-hydroxypoly(oxy-1,2-ethanediyl) polymer (also known as a octylphenoxypolyethoxyethanol) and a 4-(1,1,3,3-Tetramethylbutyl)phenol polymer with formaldehyde and oxirane.

8. (Cancelled) ~~A pharmaceutical formulation according to claim 6 wherein the surfactant is a 4-(1,1,3,3-Tetramethylbutyl)phenol polymer with formaldehyde and oxirane.~~

9. (Cancelled) ~~A pharmaceutical formulation comprising an aqueous carrier liquid having dissolved therein (a) an ester of fluticasone or a solvate thereof as medicament (b) a solubilising agent for assisting the solubilisation of the medicament in the aqueous carrier liquid, and (c) a hydroxy containing organic co-solvating agent or phosphatidyl choline.~~

10. (Original) A pharmaceutical formulation according to claim 7 which further has dissolved therein a hydroxy containing organic co-solvating agent or phosphatidyl choline.

11. (Cancelled) ~~A pharmaceutical formulation according to claim 9 wherein the hydroxy containing organic co-solvating agent is dextrose.~~

12. (Previously Amended) A pharmaceutical formulation according to claim 10 wherein the hydroxy containing organic co-solvating agent is dextrose.

13. (Previously Amended) A container containing a pharmaceutical formulation according to claim 4 fitted with a metering valve.

14. (Original) A device adapted for intranasal delivery of a pharmaceutical formulation comprising a container according to claim 13.

15. (Previously Amended) A method of treatment of inflammatory and/or allergic conditions of the nasal passages which comprises administering to the nose a pharmaceutical formulation according to claim 4.

16. (Cancelled) ~~A container containing a pharmaceutical formulation according to claim 6 fitted with a metering valve.~~

17. (Cancelled) ~~A device adapted for intranasal delivery of a pharmaceutical formulation comprising a container according to claim 16.~~

18. (Cancelled) ~~A method of treatment of inflammatory and/or allergic conditions of the nasal passages which comprises administering to the nose a pharmaceutical formulation according to claim 6.~~

19. (Cancelled) ~~A container containing a pharmaceutical formulation according to claim 9 fitted with a metering valve.~~

20. (Cancelled) ~~A device adapted for intranasal delivery of a pharmaceutical formulation comprising a container according to claim 19.~~

21. (Cancelled) ~~A method of treatment of inflammatory and/or allergic conditions of the nasal passages which comprises administering to the nose a pharmaceutical formulation according to claim 9.~~

Add the following new claims:

22. (new) The pharmaceutical composition according to claim 4, which further comprises at least one additional therapeutically active agent.

23. (new) The pharmaceutical composition according to claim 22, wherein said at least one additional therapeutically active agent is a β_2-adrenoreceptor agonist.

24. (new) The pharmaceutical composition according to claim 22, wherein said at least one additional therapeutically active agent is a PDE4 inhibitor.

25. (new) The pharmaceutical composition according to claim 23, wherein said β_2-adrenoreceptor agonist is at least one selected from the group consisting of salmeterol, salbutamol, formoterol, fenoterol and terbutaline and salts thereof.

26. (new) The pharmaceutical composition according to claim 22, wherein said at least one additional therapeutically active agent is an anti-histamine, anti-inflammatory agent or antiinfective agent.

27. (new) The pharmaceutical composition according to claim 26, wherein said anti-histamine is methapyrilene or loratadine, said anti-inflammatory agent is an NSAID and said antiinfective agent is an antibiotic or antiviral.

28. (new) The pharmaceutical composition according to claim 4, wherein the solubilising agent for assisting the solubilisation of the medicament in the aqueous carrier liquid is selected from the group consisting of Triton X-100, Tyloxapol and Triton X-305.

29. (new) The pharmaceutical composition according to claim 10, wherein the hydroxyl containing organic co-solvating agent is PEG 200, propylene glycol or dextrose.

30. (new) A method for the treatment of at least one condition selected from the group consisting of rhinitis, dermatitis, asthma and chronic obstructive pulmonary disease (COPD) in a human or animal subject, which comprises administering an effective amount of the composition as defined in claim 4 to said human or animal subject in need thereof for the treatment of said at least one condition.

31. (new) The method of treatment as recited in claim 30, wherein said composition is administered by inhalation or by nebulisation.

32. (new) An inhaler comprising the composition as defined in claim 4.